Identification
NameN-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE
Accession NumberDB07235
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 436.358
Monoisotopic: 435.068736359
Chemical FormulaC19H19Cl2N5OS
InChI KeyHHOVRZGUSBMKKU-ZDUSSCGKSA-N
InChI
InChI=1S/C19H19Cl2N5OS/c1-23-19-24-7-6-15(26-19)16-4-5-17(28-16)18(27)25-13(10-22)8-11-2-3-12(20)9-14(11)21/h2-7,9,13H,8,10,22H2,1H3,(H,25,27)(H,23,24,26)/t13-/m0/s1
IUPAC Name
N-[(2S)-1-amino-3-(2,4-dichlorophenyl)propan-2-yl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-2-carboxamide
SMILES
[H][C@@](CN)(CC1=C(Cl)C=C(Cl)C=C1)NC(=O)C1=CC=C(S1)C1=CC=NC(NC)=N1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
cAMP-dependent protein kinase catalytic subunit alphaProteinunknownNot AvailableHumanP17612 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00129 mg/mLALOGPS
logP4.14ALOGPS
logP3.7ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)14.17ChemAxon
pKa (Strongest Basic)9.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area92.93 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity114.87 m3·mol-1ChemAxon
Polarizability44.87 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8523
Caco-2 permeable-0.5641
P-glycoprotein substrateSubstrate0.5658
P-glycoprotein inhibitor INon-inhibitor0.8696
P-glycoprotein inhibitor IINon-inhibitor0.9857
Renal organic cation transporterNon-inhibitor0.7032
CYP450 2C9 substrateNon-substrate0.8268
CYP450 2D6 substrateNon-substrate0.8231
CYP450 3A4 substrateSubstrate0.5377
CYP450 1A2 substrateInhibitor0.7917
CYP450 2C9 inhibitorNon-inhibitor0.573
CYP450 2D6 inhibitorNon-inhibitor0.6479
CYP450 2C19 inhibitorInhibitor0.5642
CYP450 3A4 inhibitorNon-inhibitor0.6311
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5661
Ames testNon AMES toxic0.6954
CarcinogenicityNon-carcinogens0.874
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5890 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9861
hERG inhibition (predictor II)Non-inhibitor0.5597
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomChemical entities
Super ClassOrganic compounds
ClassBenzenoids
Sub ClassBenzene and substituted derivatives
Direct ParentAmphetamines and derivatives
Alternative ParentsThiophene carboxamides / 2-heteroaryl carboxamides / Dichlorobenzenes / Secondary alkylarylamines / 2,5-disubstituted thiophenes / Aminopyrimidines and derivatives / Aralkylamines / Aryl chlorides / Heteroaromatic compounds / Secondary carboxylic acid amides
SubstituentsAmphetamine or derivatives / 2-heteroaryl carboxamide / 1,3-dichlorobenzene / Thiophene carboxamide / Thiophene carboxylic acid or derivatives / Halobenzene / Aminopyrimidine / Secondary aliphatic/aromatic amine / Aralkylamine / Chlorobenzene
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin protein ligase binding
Specific Function:
Phosphorylates a large number of substrates in the cytoplasm and the nucleus. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which binds and ubiquitinates these subunits, leading to their subsequent proteolysis. Phosphorylates CDC25B, ABL1, NFKB1, CLDN3, PSMC5/RPT6, PJA2, RYR2, RORA and VASP. RORA is activated by phosphorylation. Re...
Gene Name:
PRKACA
Uniprot ID:
P17612
Molecular Weight:
40589.38 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on September 15, 2010 15:19 / Updated on June 11, 2017 21:06